Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIScovery podcast 50th episode CORDIScovery podcast 50th episode
Contenu archivé le 2024-06-18

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

Objectif

Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!
Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (MRSA), infections due to MDR-GNB are rapidly increasing. In a very recent report the Centers for Disease Control and Prevention concluded that Carbapenem-Resistant Enterobacteriaceae (CRE) represent an immediate public health threat that requires urgent and aggressive action (CDC: Antibiotic Resistance Threats in the United States 2013).

The epidemiology of MDR-GNB, and especially of CRE, is characterized by large heterogeneity in genotypes (with >20 reported resistance genes, such as NDM, KPC, VIM, OXA-48) and even larger heterogeneity of phenotypes, seriously hampering rapid detection of resistant types when using routine susceptibility testing. Treatment of infections caused by CRE relies on combinations of “older” antibiotics, lacking a strong evidence base of effectiveness and safety. New treatments for these infections are, therefore, urgently needed.

The COMBACTE-CARE consortium is building on the recently funded Topic 1a/b/c consortium: COMBACTE, and contains three networks: CLIN-Net, LAB-Net and STAT-Net. To fulfil the specific objectives of Topic 5 the consortium has focussed on capacity building in clinical sites in some of the new member states in south-eastern Europe, where infection rates with MDR-GNB are expected to be high. Together with high-quality study sites in countries with endemic levels of MDR-GNB (such as Israel and Greece) CLIN-Net and LAB-Net will maximize capacity to provide a highly efficient resource for the conduct of the proposed studies on ATM-AVI. Furthermore, the consortium brings in four of the most prominent MDR-GNB diagnostic research groups in Europe, able to address the diagnostic challenges for the epidemiological and clinical studies, and a highly successful – and already operational – cohort for biomarker identification in critically ill patients. Furthermore, the participation of the PENTA network offers the unique opportunity to efficiently include neonates and children in the observational studies.

The COMBACTE-CARE consortium brings together 20 academic partners (10 also partner in COMBACTE) and two CROs that build upon prior EU Commission investments which present unique expertise and capabilities to the overall project partnership.

For all these reasons, APC2 (aligned with the COMBACTE infrastructure) will (1) increase the efficiency of antibiotic R&D through analysing observational clinical and microbiological data sets and making recommendations for the development of novel antibiotic agents for MDR GNB; will (2) provide new knowledge on the clinical management and outcomes of patients (neonates/children and adults) with serious hospitalised infections and will validate this knowledge for clinical outcomes for patients in areas of emerging and endemic antibiotic resistance; will (3) support the sustainability of ND4BB supported investigator and laboratory networks (COMBACTE); will (4) conduct prospective clinical trials with novel trial designs to deliver safety, pharmacology, and proof of efficacy data for novel agents directed towards treatment of infections due to MDR pathogens, prevention or sequelae of infections due to priority pathogens; will (5) validate novel bacterial identification and follow-up diagnostics or clinical endpoints with the aim of reducing the size and cost of clinical trials; and will (6) provide new knowledge on biomarkers predicting poor outcome in patients with serious healthcare-associated infections.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: Le vocabulaire scientifique européen.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

Programmes de financement pluriannuels qui définissent les priorités de l’UE en matière de recherche et d’innovation.

Thème(s)

Les appels à propositions sont divisés en thèmes. Un thème définit un sujet ou un domaine spécifique dans le cadre duquel les candidats peuvent soumettre des propositions. La description d’un thème comprend sa portée spécifique et l’impact attendu du projet financé.

Appel à propositions

Procédure par laquelle les candidats sont invités à soumettre des propositions de projet en vue de bénéficier d’un financement de l’UE.

IMI-JU-09-2013
Voir d’autres projets de cet appel

Régime de financement

Régime de financement (ou «type d’action») à l’intérieur d’un programme présentant des caractéristiques communes. Le régime de financement précise le champ d’application de ce qui est financé, le taux de remboursement, les critères d’évaluation spécifiques pour bénéficier du financement et les formes simplifiées de couverture des coûts, telles que les montants forfaitaires.

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinateur

PFIZER LIMITED
Contribution de l’UE
Aucune donnée
Adresse
RAMSGATE ROAD
CT13 9NJ Sandwich
Royaume-Uni

Voir sur la carte
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total

Les coûts totaux encourus par l’organisation concernée pour participer au projet, y compris les coûts directs et indirects. Ce montant est un sous-ensemble du budget global du projet.
Aucune donnée

Participants (22)

Partager cette page Partager cette page sur les réseaux sociaux

Télécharger Télécharger le contenu de la page

Dernière mise à jour: 23 Février 2022

Mon livret

Permalink: https://cordis.europa.eu/project/id/115620/fr

European Union, 2025

Mon livret 0 0